BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper ...

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 4 newly-hired employees options to purchase ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CAMBRIDGE, Mass., June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the ...

The stock price of Akebia Therapeutics Inc. (NASDAQ: AKBA) has plunged by -5.30 when compared to previous closing price of 1.32, but the company has seen a -8.76% decline in its stock price over the ...

AKBA stock is trading at a margin of -12.42%, -25.70% and -15.84% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices. 3 Tiny Stocks Primed to Explode The world's greatest investor ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are ...